Compare AbbVie Inc (ABBV) vs Seagate Technology Holdings PLC (STX) Price & Performance

AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.

The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.

STX trades at $827.64, up 0.91% today, with a bearish technical signal and neutral oscillators. The stock shows strong fundamental momentum, with Q1 2026 EPS of $4.10 beating expectations of $3.51, continuing a trend of earnings beats. Revenue for 2025 reached $9.10 billion with a net income margin of 21.6%, while valuation ratios like P/E of 82.38 and P/B of 179.4 reflect high growth expectations. Recent news highlights STX as a top momentum stock amid AI-driven demand, despite sector volatility.

The outlook for STX is positive, driven by robust earnings growth and AI infrastructure demand, with a consensus price target of $955.71 implying 15% upside. Risks include high debt levels, with a debt-to-asset ratio of 73.31% in 2024, and sensitivity to memory market fluctuations, as seen in recent sell-offs. Investor sentiment remains bullish among analysts, with 51% buy ratings, but technical weakness warrants caution near-term.